Osteoporosis, and in children growth failure, are common health problems often linked to chronic inflammatory disorders and secondary to the treatment with glucocorticoids (GCs). High doses of GCs are administered systemically and/or locally to children under various conditions, including rheumatoid arthritis, inflammatory bowel disease, asthma, Crohn’s disease and ulcerative colitis. Despite the high degree of therapeutic efficacy of GCs, their use is associated with impaired bone growth and osteoporosis in treated subjects. In conditions of chronic inflammation, pro-inflammatory cytokines are released into the circulation. The most abundant of these, TNFα, IL-1β, and IL-6, are all known to directly act at the growth plate cartilage to induce apoptosis and thereby suppress bone growth. The aim of this project is to identify new drug targets allowing the prevention of short stature and osteoporosis caused by chronic inflammatory disorders and secondary to the treatment with GCs.